Tenofovir resistance and first-line antiretroviral therapy

Lancet Infect Dis. 2016 Aug;16(8):890-1. doi: 10.1016/S1473-3099(16)30137-2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active*
  • Drug Resistance, Viral / drug effects
  • HIV Infections
  • Humans
  • Reverse Transcriptase Inhibitors
  • Tenofovir*

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Tenofovir